Longevity Report · Week of September 5, 2026
Semaglutide's lifespan claim, statins after 70, rapamycin's caveats, protein's ceiling, and Lp(a)'s new drug
- Semaglutide Extends Lifespan in Aged Female Mice—Overlapping but Not Identical to Calorie RestrictionArticle — "Semaglutide Extends Lifespan in Aged Female Mice—Overlapping but Not Identical to Calorie Restriction": Two longevity researchers looked at the same study and reached opposite worries about the same missing nu…
- Statins for Healthy Over-70s: Decade-Long Trial Shows 30% Cut in First Major Cardiac EventCardiovascular mortality was identical in both arms: 2.4 events per 1000 person-years, atorvastatin versus placebo, a hazard ratio of exactly 1.00.
- Rapamycin's Lifespan Effect Flips With Diet, Sex, and Genotype in Fruit FliesTake one drug, one species, two jars of food. In flies raised on a cornmeal and torula yeast medium, rapamycin extended life in one experiment, had no effect in six, and was harmful in 19. Move the same drug to a nutrien…
- The Protein Ceiling: Ward and Tracer Data Weighed Against High-Bolus Dogma"The anabolic response to protein ingestion during recovery from exercise has no upper limit in magnitude and duration in vivo in humans."
- Kylo-11 RNAi Achieves Deep, Durable Lp(a) Lowering—But the Outcomes Bar Remains UnmetTwo experts looked at the same Kylo-11 dataset and reached almost opposite emphases in the same week.
Threads we are following
- The ongoing head-to-head lifespan experiment pitting semaglutide directly against calorie restriction—whether dieting extends survival more, less, or the same.
- Whether guideline bodies (USPSTF, ACC) will revise primary-prevention recommendations for adults 76+ in light of STAREE's event-reduction-without-mortality-benefit findings.
- Whether future human trials will stratify participants by diet, sex, and genotype to test the context-dependence seen in flies
- The multi-week lean-mass-and-function RCT: big bolus versus spread feeding, matched protein and calories, measured in kilograms of muscle and units of strength.
- Whether Kylonova's ongoing Phase 2 (with Cleveland Clinic) can move Kylo-11 toward a cardiovascular outcomes trial that proves event reduction
One issue a week. Free.
sift. reads hundreds of sources so you don't have to, and sends one issue you can actually finish. No daily noise. Unsubscribe anytime.